Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Conditions:   Solid Tumors, Adult;   Solid Tumor;   Mesothelioma (MPM);   Epithelioid Hemangioendothelioma (EHE);   NF2 Deficient Mesothelioma;   Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes;   NF2 Deficiency;   YAP1 or TAZ Gene Fusions
Intervention:   Drug: IK-930
Sponsor:   Ikena Oncology
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 9, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments